Press release

PBMI Hosts Live Webinar with CEO of Frelii, Inc. on the Future of AI, Big DNA Data and Precision Dosing

Sponsored by Businesswire

Frelii, Inc. (OTC PINK: FRLI) (“Frelii” or “the Company”) today
announced that Ian Jenkins, CEO of Frelii, will present a live webinar
on “Using AI and Big DNA Data to Advance Drug Development and Delivery.”
The free webinar, hosted by the Pharmacy Benefit Management Institute
(PBMI), will take place on Thursday, June 27, 2019 at 1:30 p.m. Eastern
Time. Register for this highly anticipated event here.

“As artificial intelligence (AI) evolves, those in the pharmaceutical
segment must become aware of the upcoming trends and the possibilities
it unlocks for drug development, delivery and precision medicine,”
Jenkins said. “While AI and big data are delivering answers to
previously unsolved questions, they are also uncovering new discoveries,
creating new strategies for treatment and opening new fields of study
that, even in the early stages, are beginning to deliver benefits that
will positively impact human health and wellness for generations.”

During this presentation, Ian Jenkins, CEO of Frelii, will discuss:

  • Why cutting-edge technology is closing the gap in precision dosing
  • How big data can reduce the cost of drug development and clinical
  • How AI and whole genome analysis can predict physical and
    psychological effects of drug interaction in an individual body
  • How physicians and pharmacists can leverage AI to move beyond murky
    recommendations of Medical Cannabis (where it is legal) into accurate,
    precise prescriptions for strain, form and dosage

Frelii Chief Executive Officer Ian Jenkins has a deep and abiding
passion for artificial intelligence and how it relates to the human
genome, particularly epigenetics and expression. Enabling the progress
and advancement of these areas has been the focus of his professional
life. Jenkins spent the early years of his career working hands-on in
research labs at both medical universities and private institutions.
Over the past decade, he has served as a senior executive and CEO in the
biotech industry, leveraging his extensive background in physiology,
technology startups, finance and product research and development.

The webinar will be hosted by PBMI, which is the nation’s leading
provider of research and education that informs, advises, and influences
the industry on drug cost management. It offers research, continuing
education, and web resources to help all critical stakeholders work
better together to optimize the overall value of drug benefit programs.

Register for this free webinar presentation at this link:

About Frelii Inc.

Frelii Inc. is a biotech company that uses human DNA gene sequencing and
artificial intelligence (AI) to assess more than 3.2 billion markers on
the human genome. The results are aligned and leveraged against its AI,
as a means of creating a very strong and powerful data platform for use
by the Health & Wellness, Healthcare, Medical Cannabis and
Pharmaceutical industries. Frelii’s technology generates accurate and
profoundly valuable insight into an individual’s DNA. The company
provides DNA Kit Packages and customized reporting for consumers,
patients and healthcare providers to ensure the ideal treatment, drugs
and dosing are a prime “fit” to the individual. For more information,
please visit
Frelii (OTC PINK: FRLI) currently trades on the OTC Pink Open Market,
which is operated by the OTC Markets Group. Investors can find Real-Time
quotes and market information for the company on

Follow Frelii online at:

Frelii Facebook Page
Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
LinkedIn Page

Safe Harbor Statement:

This release contains certain “forward-looking statements” relating to
the business of the Company. All statements, other than statements of
historical fact included herein are “forward-looking statements”
including statements regarding: the continued growth of the e-commerce
segment and the ability of the Company to continue its expansion into
that segment; the ability of the Company to attract customers and
partners and generate revenues; the ability of the Company to
successfully execute its business plan; the business strategy, plans,
and objectives of the Company; and any other statements of
non-historical information. These forward-looking statements are often
identified by the use of forward-looking terminology such as “believes,”
“expects” or similar expressions and involve known and unknown risks and
uncertainties. Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they do
involve assumptions, risks, and uncertainties, and these expectations
may prove to be incorrect. Investors should not place undue reliance on
these forward-looking statements, which speak only as of the date of
this news release. The Company’s actual results could differ materially
from those anticipated in these forward-looking statements as a result
of a variety of factors, including those discussed in the Company’s
periodic reports that are filed with the Securities and Exchange
Commission and available on its website (
All forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by these
factors. Other than as required under the securities laws, the Company
does not assume any duty to update these forward-looking statements.